Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study

Fig. 2

Illustration of the self-controlled case series model by exposure to erythrocytosis and SGLT2i. This model was applied to evaluate the association between erythrocytosis and cardiovascular outcomes, in the presence or absence of SGLT2i exposure. Four mutually exclusive risk periods included (i) SGLT2i exposure with erythrocytosis; (ii) SGLT2i exposure without erythrocytosis; (iii) absence of SGLT2i exposure with erythrocytosis; and (iv) absence of SGLT2i exposure without erythrocytosis

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840